Dr. Muanza joined the JGH Radiation Oncology Department in 2004. His dedication to his field is undisputed: in addition to his clinical duties, he is an active member of several tumor boards at various medical insitutions. He is an Assistant Professor at McGill University. His research acitivities earned him a FRSQ Chercheur – boursier clinicien Junior 1. His involovment with the Young Adult Clinic has lead to improved understanding and care for patients in the 18-39 age category.
Université de Sherbrooke, Sherbrooke, QC
Jewish General Hospital, Montreal, QC
ASTRO-NCI Fellow, National Institutes of Health, Bethesda, MD, USA
Adolescent &Young Adult Oncology (AYA)
Interaction of Ionizing Radiation and Molecular Tartgeted Therapies
Radiation-induced Normal Tissue Injury
Optical Coherence Tomography
Breast: IGRT 3D-US, Partial Breast Irradiation, Lymphedema
CNS: Biomarkers, Combined Modality Therapies for high-grade Gliomas, IGRT:Rapid Arc & FSRT
Lung: Biomarkers, Combined Modality Therapies, IGRT, SBRT
AYA: Biomarkers & Quality of Life
Dr. Thierry Muanza
Department of Oncology, Division of Radiation Oncology
Jewish General Hospital
3755 Côte Ste. Catherine Road
Montréal, Québec, H3T 1E2
Shakir SI, Pelmus M, AncaFlorea, Boileau J-F, Guiot M-C, Di Maio S, Muanza T. Synchronous Metastatic Skull Base Chordoma to the Breast: case report and literature review. Current Oncology #2896 (in press).
Mitra Heravi, Slawomir Kumala, Zakaria Rachid, Nada Tomic, Slobodan Devic, Bertrand J. Jean-Claude, Danuta Radzioch and Thierry M. Muanza. ZRBA1, a Mixed EGFR/DNA Targeting Molecule, Potentiates Radiation Response Through Delayed DNA Damage Repair Process in a Triple Negative Breast Cancer Model. International Journal of Radiation Oncology*Biology*Physics. Volume 92(2): 399-406. June 2015
Jad Alshami, Marie-Christine Guiot, Scott Owen, Petr Kavan, Neil gibson, Flavio Solca, Agnieszka Cseh, David Reardon, Thierry Muanza. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. Oncotarget 6(32). DOI: 10.18632/ oncotarget.5297. 2015.
Tamim Niazi, Gary Mok, Mitra Heravi, Te Vuong, Raquel Aloyz, Lawrence Panasci, Thierry Muanza. Effects of DNA-PK inhibition on DNA repair and cell survival in irradiated gastric cancer cell line N87. Current Oncology 2014 Apr;21(2):91-6
Heravi M, Kumala S, Rachid Z, Tomic N, Devic S, Jean-Claude BJ, Radzioch D, Muanza T. ZRBA1 a mixed EGFR/ DNA targeting molecule potentiates radiation response through delayed DNA damage repair process in a triple negative breast cancer model. Int J Radiat Oncol Biol Phys (in press, ROB-D-14_01043R2)
Alshami J, Guiot M-C, Owen S, Kavan P, Gibson N, Solca F, Cseh A, Reardon D, Muanza T. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. (in press, ACD-15-00069)
Niazi T, Mok G, Heravi M, Vuong T, Aloyz R, Panasci L, Muanza T. Effects of DNA-PK inhibition
on DNA repair and cell survival in irradiated gastric cancer cell line N87. Current Oncology 2014 Apr;21(2):91-6.
Heravi M, Tomic N, Liang L, Devic S, Holmes J, Deblois F, Radzioch D, Muanza T. Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model, Anticancer Drugs, June 2012, 23(5):525-33
Wong P, Muanza T, Hijal T, Masse L, Pillay S, Chasen M, Lowensteyn I, Gold M, Grover S. Effect of exercise in reducing breast and chest-wall pain in patients with breast cancer: a pilot study, Current Oncology, June 2012, 19(3):e129-35
Wu X, Kasymjanova G, Holcroft C, Mekouar H, Carbonneau A, Sultanem K, Muanza T, Her2 and Basal like subtypes of invasive breast cancer are associated with a higher tumor grade and rate of lymph node metastasis, 26th Annual Scientific Meeting CARO 2012 Targeting Biology, September 12-15, 2012, Ottawa, Canada, Radiotherapy & Oncology 104(S2): S94, Abstract #239
Muanza T, Heravi M, Radzioch D, Time and sequence dependency of Sorafenib in combination with ionizing radiation in metastatic breast cancer model, 26th Annual Scientific Meeting CARO 2012 Targeting Biology, September 12-15, 2012, Ottawa, Canada, Radiotherapy & Oncology 104(S2): S2, Abstract #5
Sahebjam S, Garoufalis E, Guiot M C, Muanza T,Del Maestro R, Petrecca K, Sharma R, Kavan P. Bevacisumab Use for Recurrent High-Grade Gioma at Mc Gill University Hospital Can J Neurol Sci. 40:241-246, 2013.
Krauze AV, Won M, Graves C, Corn BW, Muanza TM, Howard SP, Mahadevan A, Schultz CJ, Haas ML, Mehta MP, Camphausen KA. Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM). Biomark Res. 2013 Oct 31;1(1):29.